OncLive® Names Beth Y. Karlan, M.D., as Keynote Speaker for 2018 National Fellows Forum on Gynecologic Oncology
Published: Apr 09, 2018
CRANBURY, N.J.--(BUSINESS WIRE)-- OncLive®, the leading digital provider of resources and information for oncology professionals, is proud to announce that Beth Y. Karlan, M.D., will be the keynote speaker for the National Fellows Forum on Gynecologic Oncology taking place April 26 to 28 in Miami.
“We are thrilled to be joined by Dr. Karlan, who brings an extensive knowledge from the gyn-onc field,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company of OncLive®. “We look forward to hosting this event and hearing her insights.”
Karlan serves as director of the Women’s Cancer Program in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles. She is also director of the division of gynecologic oncology and director of the Gilda Radner Hereditary Cancer Program, and she holds the Board of Governors Chair in Gynecologic Oncology. Her clinical areas of practice primarily include cervical cancers, fallopian tube cancer, ovarian cancer, pelvic mass, vulvar cancers and postmenopausal bleeding.
“Dr. Kaplan has made tremendous contributions to the field of obstetrics and gynecology oncology,” said Robert Goldsmith, vice president of OncLive®. “The attending fellows will gain great insight from her throughout her keynote address.”
For more information about the event, visit onclive.com/oncfellows-forum.
A digital platform of resources for practicing oncologists, OncLive® offers oncology professionals information they can use to help provide the best patient care. OncLive.com is the official website for MJH Associates’ Oncology Specialty Group, which publishes OncologyLive®, Oncology Nursing News® and more. MJH Associates is a full-service health care communications company offering education, research and medical media, including curetoday.com and CURE® magazine, the largest U.S. consumer publication focused entirely on cancer. Combining science and humanity to make cancer understandable, CURE® reaches patients, cancer centers and advocacy groups.